What question did this study set out to answer?

February 12, 2026Shock0 citations

Clinical and Immunologic Effects of Extracorporeal Cytokine Removal in Patients with Septic Shock: A Randomized Controlled Trial

CLChristopher Lotz JHJohannes Heckelmann CLClara Lendzian

Key Points

To evaluate the clinical and immunologic effects of extracorporeal cytokine removal in septic shock patients.
Single-center randomized controlled trial
Included 31 adult patients with septic shock and IL-6 > 500 pg/ml
Intervention group received CytoSorb hemoadsorption plus standard care
Control group received standard care per sepsis guidelines
Primary outcome was cumulative norepinephrine dose over 72 hours
Cumulative norepinephrine dose in control group was 78 mg versus 100.7 mg in intervention group (p = 0.09)
Total vasopressor dose per hour was lower in control group (1.2 mg) versus intervention group (2.5 mg; p = 0.0053)
Survival at 48 hours was 100% in control group versus 64% in intervention group (p = 0.01)
Survival at 72 hours was 94% in control group versus 57% in intervention group (p = 0.03)
No differences in immune response were observed between groups

Abstract

Background: Immune dysregulation and excessive cytokine release characterize the early phase of septic shock. Extracorporeal hemoadsorption with the CytoSorb® device aims to restore immune balance by removing inflammatory mediators. Currently clinical benefits remain uncertain. Methods: In a single-center randomized controlled trial, 31 adult patients with septic shock, extracorporeal circuit and Interleukin-6 > 500 pg/ml were included. The control group received standard care according to sepsis guidelines. The intervention group received standard care plus CytoSorb hemoadsorption. The primary outcome was the cumulative norepinephrine dose over 72 hours. Secondary outcomes included clinical and immunological endpoints. Results: Between February 2022 and July 2023, 58 patients with septic shock and hyperinflammation were screened for study inclusion. 17 patients were randomized to the control group, 14 patients received extracorporeal cytokine removal. Hemoadsorption started within 24 h after onset of septic shock in 93 % of cases. The cumulative norepinephrine dose in 72 hours was 78 mg (52.7 – 117.8 mg) in the control group and 100.7 mg (66.4 – 190.8 mg) with extracorporeal cytokine removal (p = 0.09). The total vasopressor dose per hour alive in the first 72 hours was significantly lower in the control group compared to extracorporeal hemoadsorption (1.2 mg, 0.8 – 2.0 mg versus 2.5 mg, 1.7 – 3.3 mg; p = 0.0053). Survival at 48 hours (100 %, n = 17/17 versus 64 %, n = 9/14; p = 0.01) and 72 hours (94 %, n = 16/17 versus 57 %, n = 8/14; p = 0.03) after onset of septic shock was higher in the control group. ICU mortality, length of stay, duration of septic shock, and other clinical outcomes did not differ between the groups. The humoral immune response including pro- and anti-inflammatory cytokines was similar between groups. Compared to controls, patients with extracorporeal cytokine removal had significantly lower lymphocyte percentages during the first three days of septic shock (6.2 %, 5.0 – 17.4 % versus 2.5 %, 2.1 – 5.6 %; p = 0.04), whereas leukocyte and lymphocyte subsets as well as cytotoxic capacities were not altered by hemoadsorption. Conclusion: Early initiation of extracorporeal hemoadsorption in patients with septic shock did not improve vasopressor requirements or clinical outcomes and no effects on the immune response were observed.

KI fragen

Bookmark

View Full Paper